ER 100
Alternative Names: ER-100Latest Information Update: 13 Oct 2026
At a glance
- Originator Harvard University
- Developer Life Biosciences
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference; Kruppel-like factor 4 replacements; Octamer transcription factor-3 replacements; SOXB1 transcription factor replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Ischaemic optic neuropathy; Open-angle glaucoma
Most Recent Events
- 09 Oct 2026 Interim efficacy and adverse events data from a phase I trial in Open-angle glaucoma released by Life Biosciences
- 02 Mar 2026 Phase-I clinical trials in Ischaemic-optic-neuropathy in USA (Intravitreous) (NCT07290244)
- 02 Mar 2026 Phase-I clinical trials in Open-angle glaucoma in USA (Intravitreous) (NCT07290244)